Kairos Pharma Stock Forecast - Simple Moving Average
| KAPA Stock | 0.72 0.04 5.26% |
Kairos Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Kairos Pharma stock prices and determine the direction of Kairos Pharma's future trends based on various well-known forecasting models. We recommend always using this module together with an analysis of Kairos Pharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
At this time, the RSI of Kairos Pharma's share price is approaching 41. This indicates that the stock is in nutural position, most likellhy at or near its support level. The main point of RSI analysis is to track how fast people are buying or selling Kairos Pharma, making its price go up or down. Momentum 41
Sell Extended
Oversold | Overbought |
EPS Estimate Next Quarter (0.07) | EPS Estimate Current Year (0.20) | EPS Estimate Next Year (0.33) | Wall Street Target Price 8.3333 |
Using Kairos Pharma hype-based prediction, you can estimate the value of Kairos Pharma from the perspective of Kairos Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The Simple Moving Average forecasted value of Kairos Pharma on the next trading day is expected to be 0.72 with a mean absolute deviation of 0.04 and the sum of the absolute errors of 2.57. Kairos Pharma after-hype prediction price | USD 0.72 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Kairos Pharma to cross-verify your projections. Kairos Pharma Additional Predictive Modules
Most predictive techniques to examine Kairos price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kairos using various technical indicators. When you analyze Kairos charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Kairos Pharma Simple Moving Average Price Forecast For the 28th of January
Given 90 days horizon, the Simple Moving Average forecasted value of Kairos Pharma on the next trading day is expected to be 0.72 with a mean absolute deviation of 0.04, mean absolute percentage error of 0, and the sum of the absolute errors of 2.57.Please note that although there have been many attempts to predict Kairos Stock prices using its time series forecasting, we generally do not recommend using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Kairos Pharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Kairos Pharma Stock Forecast Pattern
| Backtest Kairos Pharma | Kairos Pharma Price Prediction | Buy or Sell Advice |
Kairos Pharma Forecasted Value
In the context of forecasting Kairos Pharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Kairos Pharma's downside and upside margins for the forecasting period are 0.01 and 6.68, respectively. We have considered Kairos Pharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Kairos Pharma stock data series using in forecasting. Note that when a statistical model is used to represent Kairos Pharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 110.5453 |
| Bias | Arithmetic mean of the errors | 0.0098 |
| MAD | Mean absolute deviation | 0.0428 |
| MAPE | Mean absolute percentage error | 0.0523 |
| SAE | Sum of the absolute errors | 2.57 |
Predictive Modules for Kairos Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kairos Pharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Kairos Pharma After-Hype Price Density Analysis
As far as predicting the price of Kairos Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kairos Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kairos Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Kairos Pharma Estimiated After-Hype Price Volatility
In the context of predicting Kairos Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kairos Pharma's historical news coverage. Kairos Pharma's after-hype downside and upside margins for the prediction period are 0.04 and 6.64, respectively. We have considered Kairos Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Kairos Pharma is abnormally volatile at this time. Analysis and calculation of next after-hype price of Kairos Pharma is based on 3 months time horizon.
Kairos Pharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Kairos Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kairos Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kairos Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.53 | 5.96 | 0.24 | 0.03 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.72 | 0.72 | 0.00 |
|
Kairos Pharma Hype Timeline
Kairos Pharma is now traded for 0.72. The entity has historical hype elasticity of -0.24, and average elasticity to hype of competition of -0.03. Kairos is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is projected to be very small, whereas the daily expected return is now at -0.53%. %. The volatility of related hype on Kairos Pharma is about 10456.14%, with the expected price after the next announcement by competition of 0.69. About 41.0% of the company outstanding shares are owned by corporate insiders. The book value of Kairos Pharma was now reported as 0.37. The company recorded a loss per share of 0.31. Kairos Pharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 9 days. Check out Historical Fundamental Analysis of Kairos Pharma to cross-verify your projections.Kairos Pharma Related Hype Analysis
Having access to credible news sources related to Kairos Pharma's direct competition is more important than ever and may enhance your ability to predict Kairos Pharma's future price movements. Getting to know how Kairos Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kairos Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| LIXT | Lixte Biotechnology Holdings | 0.15 | 10 per month | 0.00 | (0.10) | 7.19 | (7.45) | 19.11 | |
| PTHS | Pelthos Therapeutics | 0.15 | 23 per month | 0.00 | (0.06) | 8.39 | (9.00) | 25.75 | |
| LEXX | Lexaria Bioscience Corp | 0.15 | 17 per month | 8.90 | 0 | 8.94 | (9.68) | 42.53 | |
| CASI | CASI Pharmaceuticals | (0.02) | 6 per month | 0.00 | (0.15) | 5.88 | (7.69) | 32.11 | |
| ALLR | Allarity Therapeutics | 0.15 | 26 per month | 0.00 | (0.07) | 7.07 | (7.48) | 19.82 | |
| CLSD | Clearside Biomedical | 0.15 | 2 per month | 0.00 | (0.27) | 7.96 | (17.54) | 83.67 | |
| CING | Cingulate | 0.15 | 2 per month | 4.50 | 0.1 | 7.46 | (6.75) | 20.19 | |
| BCTX | Briacell Therapeutics Corp | (1.35) | 8 per month | 0.00 | (0.07) | 13.96 | (9.09) | 98.43 | |
| ENTO | Entero Therapeutics | (0.05) | 24 per month | 0.00 | (0.01) | 16.86 | (17.06) | 39.61 | |
| PULM | Pulmatrix | (0.05) | 15 per month | 0.00 | (0.15) | 6.62 | (5.75) | 51.95 |
Other Forecasting Options for Kairos Pharma
For every potential investor in Kairos, whether a beginner or expert, Kairos Pharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Kairos Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Kairos. Basic forecasting techniques help filter out the noise by identifying Kairos Pharma's price trends.Kairos Pharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kairos Pharma stock to make a market-neutral strategy. Peer analysis of Kairos Pharma could also be used in its relative valuation, which is a method of valuing Kairos Pharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Kairos Pharma Market Strength Events
Market strength indicators help investors to evaluate how Kairos Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kairos Pharma shares will generate the highest return on investment. By undertsting and applying Kairos Pharma stock market strength indicators, traders can identify Kairos Pharma entry and exit signals to maximize returns.
Kairos Pharma Risk Indicators
The analysis of Kairos Pharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Kairos Pharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting kairos stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.43 | |||
| Standard Deviation | 5.81 | |||
| Variance | 33.76 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Kairos Pharma
The number of cover stories for Kairos Pharma depends on current market conditions and Kairos Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kairos Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kairos Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Kairos Pharma Short Properties
Kairos Pharma's future price predictability will typically decrease when Kairos Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kairos Pharma often depends not only on the future outlook of the potential Kairos Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kairos Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 11.4 M | |
| Cash And Short Term Investments | 1.3 M |
Check out Historical Fundamental Analysis of Kairos Pharma to cross-verify your projections. For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kairos Pharma. If investors know Kairos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kairos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kairos Pharma is measured differently than its book value, which is the value of Kairos that is recorded on the company's balance sheet. Investors also form their own opinion of Kairos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Kairos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kairos Pharma's market value can be influenced by many factors that don't directly affect Kairos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kairos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kairos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kairos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.